Compared To US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs

Health Affairs

Volumn 32, Issue 4, 2013, Pages 762-770

  Cohen, Joshua ^a   Malins, Ashley ^b   Shahpurwala, Zainab ^c  

^a TUFTS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABAZITAXEL; CETUXIMAB; ERIBULIN; IMATINIB; IPILIMUMAB; IRINOTECAN; OFATUMUMAB; OXALIPLATIN; PAZOPANIB;

ARTICLE; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; DECISION MAKING; DRUG COST; DRUG MARKETING; EUROPE; EVIDENCE BASED PRACTICE; FRANCE; GERMANY; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; KIDNEY CANCER; MELANOMA; NETHERLANDS; PROSTATE CANCER; REIMBURSEMENT; UNITED KINGDOM; UNITED STATES;

ANTINEOPLASTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; COST CONTROL; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COSTS; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE PART D; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84877979268     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0707     Document Type: Article

References (51)

1. Mulcahy N. Time to consider cost in evaluating cancer drugs in United States? Medscape Today [serial on the Internet]. 2009 Jul 14 [cited 2013 Feb 26; free registration required]. Available from: http://www.medscape.com/viewarticle/705689
2. Congressional Budget Office. Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role [Internet]. Washington (DC): CBO; 2007 Dec [cited 2013 Feb 26]. (Pub. No. 2975). Available from: http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/88xx/doc8891/12-18-comparativeeffectiveness.pdf
3. Neumann P. Using cost-effectiveness analysis to improve health care: opportunities and barriers. New York (NY): Oxford University Press; 2005.
4. Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol. 2010; 28(20):3234-8.
5. Cohen J, Looney W. Re: how much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2010;102(15):1207-10.
6. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044-8.
7. Tunis S. Reflections on science, judgment, and value in evidencebased decision making: a conversation with David Eddy. Health Aff (Millwood). 2007;26(4):w500-15. DOI: 10.1377/hlthaff.26.4.w500.
8. Nadler E, Eckert B, Neumann P. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006; 11(2):90-5.
9. Chalkidou K, Anderson G. Comparative effectiveness research: international experiences and implications for the United States [Internet]. Washington (DC): AcademyHealth; 2009 Jul [cited 2012 Jan 6]. Available from: http://www.academyhealth.org/files/publications/CER_International_Experience_09%20(3).pdf
10. Wilking N, Jönsson B. A pan- European comparison regarding patient access to cancer drugs [Internet]. Stockholm: Karolinska Institute; 2007 [cited 2012 Jan 5]. Available from: http://ki.se/content/1/c4/33/16/Cancer_Report.pdf
11. Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33(2):225-47.
12. Cohen J. The new Dutch health insurance system and its implications for pharmaceutical innovation. Int J Pharm Healthc Mark. 2007;1(3): 214-25.
13. Cohen J, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy. 2006;5(3):177-87.
14. Bridges J, Cohen J, Grist P, Muhlbacher A. International experience with comparative effectiveness research: case studies from England/Wales and Germany. In: Dor A, editor. Pharmaceutical markets and insurance worldwide. Bingley (UK): Emerald Books; 2010. p. 29-50.
15. Thorpe KE, Howard D. Health insurance and spending among cancer patients. Health Aff (Millwood). 2003;22:w3-189-98. DOI: 10.1377/ hlthaff.w3.189.
16. Liang SY, Haas JS, Phillips KA. Medicare formulary coverage for top-selling biologics. Nat Biotechnol. 2009;27(12):1082-4.
17. Food and Drug Administration. NME drug and new biologic approvals [Internet]. Silver Spring (MD): FDA; [last updated 2011 Nov 4; cited 2013 Feb 26]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Drugand BiologicApprovalReports/ucm121136.htm
18. European Medicines Agency [home page on the Internet]. London: EMA; [cited 2013 Feb 26]. Available from: http://www.ema.europa.eu
19. IMS Health [home page on the Internet]. Falls Church (VA): IMS Health; 2013 [cited 2013 Feb 26]. Available from: http://www.imshealth.com
20. Dutch Board of Insurers. Cost of medicines [Internet]. Diemen (The Netherlands): CVZ; [cited 2013 Mar 2]. Dutch. Available from: http://www.medicijnkosten.nl
21. French Health Insurance [home page on the Internet]. Paris: AMELI; [cited 2013 Mar 2]. French. Available from: http://www.ameli.fr
22. XE. XE currency converter [Internet]. XE; [cited 2013 Feb 26]. Available from: http://www.xe.com
23. Thomson Reuters. Physicians" desk reference: red book 2010. Montvale (NJ): Thomson Reuters; 2011.
24. Department of Veterans Affairs. Drug pharmaceutical prices [Internet]. Washington (DC): The Department; [updated 2013 Feb 26; cited 2013 Feb 26]. Available from: http://www.pbm.va.gov/DrugPharmaceuticalPrices.aspx
25. Anderson GF, Reinhardt UE, Hussey PS, Petrosyan V. It"s the prices, stupid: why the United States is so different from other countries. Health Aff (Millwood). 2003;22(3):89-105.
26. Centers for Medicare and Medicaid Services. Medicare Part B drug average sales price [Internet]. Baltimore (MD): CMS; [cited 2013 Feb 26]. Available from: http://www.cms.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp
27. Medicare.gov. Medicare plan finder [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [cited 2012 Jun 1]. Available from: http://www.medicare.gov/MPDPF/Public/Include/DataSection/Questions/MPDPFIntro.asp
28. French Health Authority [home page on the Internet]. Saint-Denis La Plaine (France): HAS; [cited 2013 Mar 2]. French. Available from: http://www.has-sante.fr
29. National Institute for Health and Clinical Excellence [home page on the Internet]. London: NICE; [cited 2013 Feb 26]. Available from: http://www.nice.org.uk
30. Institute for Quality and Efficiency in Health Care [home page on the Internet]. Cologne (Germany): IQWiG; [last updated 2013 Feb 15; cited 2013 Feb 26]. Available from: https://www.iqwig.de/institute-forquality-and-efficiency-in-health.2.en.html
31. CMS.gov.Welcome to the Medicare Coverage Database [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [cited 2013 Feb 26]. Available from: http://www.cms.gov/mcd/search.asp?clickon=search
32. Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health Aff (Millwood). 2008;27(1):221-33.
33. Roughead EE, Lopert R, Sansom LN. Prices for innovative pharmaceuticals that provide health gain: a comparison between Australia and the United States. Value Health. 2007;10(6):514-20.
34. Garber A. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004;23:w4-284-96. DOI: 10.1377/hlthaff.w4.284.
35. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide populationbased study (CONCORD). Lancet Oncol. 2008;9(8):730-56.
36. Philipson T, Eber M, Lakdawalla DN, Corral M, Conti R, Goldman DP. An analysis of whether higher health care spending in the United States versus Europe is "worth it" in the case of cancer. Health Aff (Millwood). 2012;31(4):667-75.
37. To access the Appendix, click on the Appendix link in the box to the right of the article online.
38. Trotta F, Leufkens HG, Schellens JH, Laing R, Tafuri G. Evaluation of oncology drugs at European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol. 2011; 29(16):2266-72.
39. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Health Aff (Millwood). 2011;30(7):1375-81.
40. Institute for Quality and Efficiency in Health Care. Cabazitaxel- Nutzenbewertung gemäß § 35a SGB V [Internet]. Cologne (Germany): IQWiG; 2012 Jan 12 [cited 2013 Mar 15]. German. Available from: https://www.iqwig.de/download/A11-24_Cabazitaxel_Nutzenbewertung__35a_SGB_V.pdf
41. Cohen J,Wilson A, Faden L. Off-label use reimbursement. Food Drug Law J. 2009;64(2):391-403.
42. CMS.gov. Proposed decision memo for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG-00422N) [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [cited 2013 Feb 27]. Available from: http://www.cms.gov/medicarecoverage-database/details/ncaproposed-decision-memo.aspx?NCAId=247&ver=7&NcaName=Autologous+Cellular+Immunotherapy+Treatment+of+Metastatic+Prostate+Cancer&bc=BEAAAAAAEAAA&
43. Government Accountability Office. Medicare Part D: spending, beneficiary cost sharing, and cost containment efforts for high-cost drugs eligible for a specialty tier [Internet]. Washington (DC): GAO; 2010 Jan [cited 2013 Feb 27]. (GAO-10-242). Available from: http://www.gao.gov/assets/310/300528.pdf
44. Jirillo A, Vascon F, Giacobbo M. Bevacizumab in advanced cancer, too much or too little? Ann Oncol. 2008;19(10):1817-8.
45. Robinson J. Insurers" strategies for managing the use and cost of biopharmaceuticals. Health Aff (Millwood). 2006;25(5):1205-17.
46. Faden R, Chalkidou K, Appleby J, Waters H, Leider J. Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q. 2009;87(4): 789-819.
47. Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki P, Nasser M, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q. 2009;87(2):339-67.
48. Mechanic D. Muddling through elegantly: finding the proper balance in rationing. Health Aff (Millwood). 1997;16(5):83-92.
49. PRNewswire [Internet]. Franklin Lakes (NJ). Press release, Cancer drugs emerging as top driver of specialty drug spending; 2009 Oct 8 [cited 2013 Feb 27]. Available from: http://www.prnewswire.com/newsreleases/cancer-drugs-emerging-astop-driver-of-specialty-drugspending-63745542.html
50. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood). 2010;29(1):196-202.
51. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases-a case study in oncology. Can J Clin Pharmacol. 2009;16(2):e273-81.